Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database - Zheng - British Journal of Clinical Pharmacology - Wiley Online Library
Secukinumab, the first IL-17A inhibitor, is widely used to treat immune diseases, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Here, we aimed to explore the clinical characteristics, outcomes, and time to onset of the four main toxicities of secukinumab, using post-marketing data. To read the full article, choose Open Athens “Institutional Login” and search for “Midlands Partnership”.
